Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

Matsumoto, Kinnosuke; Tamiya, Akihiro; Matsuda, Yoshinobu; Taniguchi, Yoshihiko; Atagi, Shinji; Kawachi, Hayato; Tamiya, Motohiro; Tanizaki, Satoshi; Uchida, Junji; Ueno, Kiyonobu; Yanase, Takafumi; Suzuki, Hidekazu; Hirashima, Tomonori

doi:10.21037/tlcr-20-1263

Cited by 13 publications

(13 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The comparative clinical trial of DTX/RAM versus placebo/DTX or the REVEL trial showed survival benefits as a second-line treatment of stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy [ 7 ]. Recent studies have also revealed the efficacy of the DTX/RAM combination therapy in patients with a history of ICI treatment [ 8 , 9 , 10 , 11 , 12 , 13 , 14 ]. Although the combination of chemotherapy and ICIs is currently becoming the standard regimen as the first-line treatment of advanced NSCLC, there is an insufficient number of studies regarding the use of chemotherapy and ICI combination as a second-line or later-line therapy.…”

Section: Introductionmentioning

confidence: 99%

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

Nishimura

Fujimoto

Okano

et al. 2022

Cancers

View full text Add to dashboard Cite

Reports on the efficacy of second-line treatment with cytotoxic agents after treatment with immune checkpoint inhibitors are limited. Here, we retrospectively evaluated patients in the real-world clinical practice treated with docetaxel or docetaxel plus ramucirumab. Ninety-three patients treated with docetaxel or docetaxel plus ramucirumab as a second- or later-line therapy were included. The patients were categorized into the following four treatment groups: docetaxel group (n = 50), docetaxel/ramucirumab group (n = 43) and pretreated (n = 45) and untreated (n = 48) with immune checkpoint inhibitor groups. The docetaxel/ramucirumab group showed an overall response rate of 57.1% in patients pretreated with immune checkpoint inhibitors and 20% in untreated patients. The docetaxel group showed an overall response rate of 15.4% in patients pretreated with immune checkpoint inhibitors and 5.0% in untreated patients. The median time-to-treatment failure and the median survival time were longer in the docetaxel/ramucirumab group than in the docetaxel group in both immune checkpoint inhibitor-pretreated and -untreated groups. There was no difference in time-to-treatment failure and overall survival between immune checkpoint inhibitor-pretreated and -untreated groups in each docetaxel and docetaxel/ramucirumab treatment group. In conclusion, our real-world data show that the addition of ramucirumab to docetaxel was superior to docetaxel monotherapy for improving time-to-treatment failure and overall survival, irrespective of previous treatment with immune checkpoint inhibitors.

show abstract

Section: Introductionmentioning

confidence: 99%

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

Nishimura

Fujimoto

Okano

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that ECOG‐PS = 2 is a poor prognostic factor for docetaxel alone or docetaxel plus ramucirumab therapy in previously treated patients with NSCLC. 25 , 26 We retrospectively demonstrated that a poor PS (ECOG‐PS = 2) was an independent prognostic factor for PFS and OS in the second‐line setting after chemoimmunotherapy. Therefore, the decision to use second‐line therapy following chemoimmunotherapy for NSCLC patients with a poor PS should be made with caution.…”

Section: Discussionmentioning

confidence: 99%

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

et al. 2021

View full text Add to dashboard Cite

Background: Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non-small-cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second-line treatment after chemoimmunotherapy is crucial for improving clinical outcomes. Methods: Of 88 enrolled patients with advanced NSCLC who received chemoimmunotherapy, we retrospectively evaluated 33 who received second-line chemotherapy after progression of chemoimmunotherapy at six centers in Japan. Among them, 18 patients received docetaxel plus ramucirumab and 15 patients received single-agent chemotherapy.Results: The objective response rate in patients treated with docetaxel plus ramucirumab was significantly higher than that in patients treated with a single-agent chemotherapy regimen (55.6% vs. 0%, p < 0.001). The median progression-free survival (PFS) of patients who received docetaxel plus ramucirumab and single-agent chemotherapy was 5.8 months and 5.0 months, respectively (log-rank test p = 0.17). In the docetaxel plus ramucirumab regimen group, patients who responded to chemoimmunotherapy for ≥8.8 months had a significantly longer response to docetaxel plus ramucirumab than those who responded for <8.8 months (not reached vs. 4.1 months, log-rank test p = 0.003). In contrast, in the single-agent chemotherapy group, there was no significant difference in PFS between the ≥8.8and <8.8-month PFS groups with chemoimmunotherapy (5.0 vs. 1.6 months, log-rank test p = 0.66). Conclusion: Our retrospective observations suggest that the group with longer PFS with chemoimmunotherapy might be expected to benefit from docetaxel plus ramucirumab treatment in second-line settings for patients with advanced NSCLC.

show abstract

“…Several researchers have retrospectively analyzed RAM and DOC combination therapy [11][12][13][14][15]. Harada et al demonstrated that the PFS of patients who received RAM and DOC after ICI was more than twice that of those who did not, showing a signi cant difference (5.7 months vs. 2.3 months, p = 0.020) [13].…”

Section: Introductionmentioning

confidence: 99%

Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study

Tanizaki

Matsumoto

Tamiya

et al. 2023

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

ObjectivesRamucirumab (RAM) and docetaxel (DOC) are commonly used after rst-line therapy for advanced nonsmall-cell lung cancer (NSCLC). Therefore, we aimed to elucidate sequencing strategies of RAM and DOC following prior treatments, including immune checkpoint inhibitor (ICI), cytotoxic agent (CTx) alone, bevacizumab (BEV), and tyrosine kinase inhibitor (TKI). MethodsWe recruited patients with NSCLC who received RAM and DOC and compared the groups with and without prior ICI, CTx alone, BEV, and TKI, respectively. By tumor response to such treatments, the patients were further classi ed into "complete response (CR) + partial response (PR)," "stable disease," and "progressive disease" groups, respectively. We compared RAM and DOC e cacy among these groups. ResultsIn total, 237 patients were registered. In the group with prior ICI, the objective response rate and disease control rate were signi cantly higher than those without prior ICI (p = 0.012 and 0.028, respectively), and the median progression-free survival (PFS) was also signi cantly longer (p = 0.027). There were no signi cant differences in PFS between the groups with and without CTx alone, BEV, and TKI. Multivariate analysis revealed that prior ICI was an independent factor associated with better PFS. Furthermore, the prior ICI group with CR + PR signi cantly prolonged PFS compared to the group without prior ICI (p = 0.013). ConclusionRAM and DOC may be preferably administered after ICI, rather than after CTx alone, BEV, or TKI, and furthermore, enhanced if the prior ICI has a favorable tumor response.

show abstract

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

Cited by 13 publications

References 41 publications

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study

Contact Info

Product

Resources

About